Drugs / Haploidentical donor CD34+ cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01682226 | Sep 2012 → Jan 2021 | leukemia, lymphoma, myelodysplastic syndrome | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Haploidentical donor CD34+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01682226 ↗ |
| Modality | Cell therapy | “additional T-cell depleted PBSC from a haplo-identical donor” NCT01682226 ↗ |